Quantum BioPharma Completes Warrant Expiration and Confirms CVR Distribution Date for Potential Litigation Proceeds

Quantum BioPharma Ltd. has reached a significant milestone in its corporate financing history with the expiration of the final tranche of warrants issued to hedge funds and investment funds. The company announced that 53,147 warrants expired at 5 p.m. ET, representing the remaining portion of what was originally 3,454,543 warrants issued as part of a 2020 financing arrangement prior to the company's reverse stock split. This expiration marks the conclusion of a multi-year warrant program that has been part of Quantum BioPharma's capital structure.

Simultaneously, the company reaffirmed October 27, 2025 as the definitive record date for the distribution of contingent value rights to Class B Subordinate Voting Shareholders. These CVRs will be distributed on a one-for-one basis, meaning shareholders will receive one CVR for each share they hold as of the record date. The significance of these CVRs lies in their potential value - they entitle holders to receive a pro rata share of 10% to 50% of any net proceeds from Quantum BioPharma's substantial $700 million litigation against major financial institutions including CIBC World Markets and RBC Dominion Securities.

The litigation represents one of the most substantial potential value drivers for Quantum BioPharma shareholders. The contingent value rights structure provides shareholders with direct participation in any successful outcome from this legal action without requiring additional investment. The range of 10% to 50% of net proceeds indicates that the company has structured the distribution to provide meaningful participation while retaining a significant portion for corporate purposes. This approach balances shareholder returns with the company's ongoing operational needs and strategic initiatives.

The warrant expiration and CVR confirmation come at a pivotal time for Quantum BioPharma as the company continues to advance its biopharmaceutical pipeline. The resolution of these financial instruments simplifies the company's capital structure and provides clearer visibility into shareholder value potential from both operational progress and the litigation outcome. Investors can access the full details of these developments through the official press release available at https://ibn.fm/g52XC. The combination of these corporate actions represents important steps in Quantum BioPharma's ongoing efforts to maximize shareholder value through both its core business operations and strategic financial management.